Vidofludimus calcium is under clinical development by Immunic and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Neuroendocrine Tumors.

Zigakibart is under clinical development by Novartis and currently in Phase III for IgA Nephropathy (Berger's Disease).

Danazol is under clinical development by Viramal and currently in Phase II for Endometriosis. According to GlobalData, Phase II drugs for Endometriosis have a 30% phase transition success rate (PTSR) ...

Novaferon is under clinical development by Genova Biotech and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

CFTX-1554 is under clinical development by Eli Lilly and Co and currently in Phase I for Peripheral Neuropathic Pain.

EF-001 is under clinical development by Everfront Biotech and currently in Phase II for High-Grade Glioma. According to GlobalData, Phase II drugs for High-Grade Glioma does not have sufficient ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

ENERGIF-703 is under clinical development by Energenesis Biomedical and currently in Phase III for Diabetic Foot Ulcers.

CY-101 is under clinical development by Cytovation and currently in Phase II for Liver Cancer. According to GlobalData, Phase II drugs for Liver Cancer have a 31% phase transition success rate (PTSR) ...

VIR-5818 is under clinical development by Vir Biotechnology and currently in Phase II for Metastatic Breast Cancer.